We all know that Pharmaceutical R&D is expensive, companies need to be reimbursed for failed investments, fund studies, have money for future developments and the list goes on and on. Is there more to pricing than "what the market will bear?" Read full article here. (Source: MIT Technology […]
Healthcare CEOs – Can’t Sleep At Night? Try HINs Dream Rx Now!
HIN's ninth annual industry forecast, provides both a handle on what's keeping healthcare CEOs up at night and a dream prescription for sounder program management in 2014. The advice in this 40-page resource is supplemented with data from HIN's tenth annual Healthcare Trends and Forecast survey […]
PRO Claims-Why Is The EMA Granting More Than The FDA?
There Appears to be poor concordance between the two agencies on the macro level, but upon close examination, there appears to be greater concordance than previously recognized. Full article available here. (Source: Elsevier, Dec 2013). […]
Pharmacoepidemiology Studies – What’s New In The EU?
To succesfully conduct an epidemiology study, it is important to understand the environment one is working, the regulatory demands as well as the resources available to conduct these studies. Check out the available resources summarized in this article. (Source: PRM newsletter, Dec 2013). […]
NICE Extends Role In Value Based Pricing For The NHS
The National Institute for Health and Care Excellence (NICE) will be taking a central role in Value Based Pricing (VBP) for the NHS starting in 2014. To find out more about this, Pharma IQ spoke to NICE's Chief Executive Sir Andrew Dillon about VBP and the challenges that NICE will face in its new […]
Do Health Outcomes Studies Increase Drug Costs?
The December 17, 2013 newsletter from HealthEconomics.com explored whether the growing need for health outcomes studies will lead to increased research and development costs. Despite the added cost, such studies are growing in demand because they provide data that is not currently addressed by […]
GSK’s Tafinlar – Will It Reach Germany’s Patients?
In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…Subscription required to access full article. (Source: thepharmaletter, 1/7/14). […]
HealthEconomics.com Is Spreading Its Wings!
The first live streaming event in the HE-Xpo® virtual environment will take place at 11:00am ET on January 9, 2014, and is entitled “Running Successful Trials in Emerging Regions Using Technology to Maximize Success”. For information about participating in HE-Xpo® as an exhibitor and sponsor, Email […]
Have You Heard About Evidera’s Exciting New Acquisition?
Symphony Technology Group (STG), and Evidera recently announced the acquisition of Archimedes, a San Francisco-based healthcare modeling company and wholly owned subsidiary of Kaiser Permanente. Read more about this exciting new chapter here. (Source: PRNewswire, 1/08/14) […]
Will You Be Attending The Evidence USA Exhibition In Boston This Year?
Evidence and value development in healthcare is a massive subject with topics ranging from payer engagement, observational research to the use of patient registries and local evidence generation. To breakdown the subject a little more and to give you a guide to some of the main highlights of the […]
Bayer’s Hot-Selling Eylea – Not So Hot Back Home
Sales of Bayer's Eylea have taking off since the EU greenlighted the eye drug in late in 2012. But now, Germany's cost watchdog has thrown up a roadblock for the second time. Will Eylea be able to show an advantage over its rival, Novartis' Lucentis? More here. (Source: FiercePharma, 1/3/14) […]
Obamacare – Flashbacks To The Watergate Affair?
The recent "adjustments" made to the ACA, remind this author of the "that statement is no longer operative" line used by the Nixon team, and has him asking "What's next?" Read more. (Source: First Report Managed Care, 1/2/14). […]
Do You Have A Nomination For The ISPOR 2014 Scientific Awards?
ISPOR's Scientific Awards are designed to recognize outstanding achievements in pharmacoeconomics and outcomes research and will be presented at the ISPOR 19th Annual International Meeting in Montreal, QC, Canada, May 31-June 4, 2014. Nomination requirements and detailed award descriptions can be […]
Are JAMA Guidelines Likely To Harm Patients?
JAMA published the long-awaited Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure-8 (JNC-8)guidelines December 18, 2013. In this article, David Cundiff, MD calls for states that the JNC-8 authors ignored evidence and have put forth guidelines that […]
Want to stay up-to-date with the latest in HEOR in Latin America?
In this issue, you will hear from the General Health Council of Mexico, as they present a useful description of Mexico's decision making process, and read about adopting a cost and resource use measurement instrument to the context of mental health issues in Brazil. The newsletter also features a […]
Using Carrots and Sticks To Guide Patients To The Care They Truly Need?
Bigger isn't always better, less is sometimes more, and just because it's new doesn't mean it's for you! These are some of the ideas proponents of value based insurance are hoping to spread. About 1/3 of America's healthcare spending is attributed to wasteful or ineffective care. With this new type […]
National Pharmaceutical Council 2013 Year In Review
Since the organization's founding in 1953, NPC's mission has remained the same, but the issues they have chosen to engage in have changed. Take a look back and see what 2013 issues where taken on by NPC, here. (Source: NPC, Dec 2013). […]
Could CER Help Lower Costs Of Specialty Pharmaceuticals?
Specialty pharmaceuticals are complex to manufacture and distribute, often difficult to administer, may require special patient monitoring and are a rapidly growing share of the costs to health plans. Payers are exploring ways to decrease the cost of these drugs; Comparative Effectiveness Research […]
Pragmatic Clinical Trials in 2014
With the Patient-Centered Outcomes Research Institute (PCORI) announcing plans to fund PCTs in 2014, stakeholders are going to be hearing a lot more about this type of research. Learn more about PCTs here. (Source: NPC, Dec 2013). […]
Can GSK Restore Its Reputation After Allegations Of Bribery?
GSK has been in the spotlight this year after being accused of paying almost$500m in bribes to doctors and health officials in China to boost prescribing of its drugs, with the resulting fall-out impacting its third-quarter financial results. Meanwhile, the company paid a massive $3bn settlement in […]
Will Clinical Trial Recruitment Make It In The Digital World?
There are an increasing number of clinical trial search services popping up, but efforts to harness digital channels for patient recruitment are still at an experimental stage. While more and more patients are going online for health reasons, the potential is obvious, but what is the best way to […]
Key Collaborations Needed to Move beyond the Logical Specialty Pharma Distribution Model
In order to improve distribution effectiveness, quality of care, data collection, and other health information, specialty pharmacies and healthcare groups need to focus on expanding their patient and treatment management services. Building key collaborations with third party health care groups that […]
How Can You Leverage Specialty Pharmacy in ACOs?
Join Armada Health Care as they host a complimentary webinar series addressing this topic. This 4-part webinar series includes a live forum at the upcoming 10th Annual Specialty Pharmacy Summit & Expo in Las Vegas. […]
Read the Latest Issue of Avella’s Dispensing Excellence
In the latest issue of Avella's publication, Dispensing Excellence, you will find topics ranging from the path of a specialty prescription, hepatitis specialty pharmacy selection tips, and a 2013 oncology medication review. Read the latest issue here. (Source: Avella, 1/2014) […]
CEA or MCDA – Which Will It Be?
AN ISPOR 16th Annual European Congress - Dublin session - Should Multi-Criteria Decision Analysis (MCDA) Replace Cost Effectiveness Analysis (CER) For Evaluation Of Health Care Coverage Decisions? Click the links below to see individual presentations. (Source: ISPOR 2013). Should MCDA Replace CEA […]
ISPOR Presents – The Many Perspectives on HTA
AN ISPOR 16th Annual European Congress - Dublin session - Early Engagement Between Manufacturers, HTA Assessors, and Regulators. Click the links below to see individual presentations. (Source: ISPOR 2013). Learning from the Past to Guide the Future The EMA Perspective NICE Scientific Advice: An […]
ISPOR Takes On Cystic Fibrosis
AN ISPOR 16th Annual European Congress - Dublin session - The Patient And Health Technology Assessment: Challenges And Opportunities. Click the links below to see individual presentations. (Source: ISPOR 2013). Evidence Supporting Reimbursement for a New Cystic Fibrosis Drug Health Technology […]
Study Finds Inconsistent Use Of Cost-Effectiveness Thresholds
This study looks at fundamental differences between the NHS and the Scottish Medicines Consortium (SMC), raising important policy issues - particularly in regards to the use of QALY thresholds - and then summarizes options in approaching this. Read more here. (Source: OHE, 12/12/13). […]
How To Run Successful Trials in Emerging Regions
The clinical development world is shrinking and running trials in emerging regions is becoming increasingly desirable and acceptable. This webinar, jointly presented by Pharm-Olam and ERT, will address the challenges most commonly faced by sponsor companies: managing patients, investigative sites, […]
ISPOR PRESIDENTIAL WELCOME
In his 2013-2014 Presidential Welcome William Crown, PhD, explains to ISPOR 16th Annual European Congress attendees how ISPOR is making an impact on health care decision making through our tools, best practices, and geographic diversity. Watch video here. (Source: ISPOR, 2013). […]
